Resources from the same session
LBA15 - MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)
Presenter: Matthew Goetz
Session: Proffered Paper session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA16 - Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial
Presenter: Binghe Xu
Session: Proffered Paper session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA76 - Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)
Presenter: Hope Rugo
Session: Proffered Paper session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Breast cancer, metastatic
Resources:
Webcast
210O - Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
Presenter: Antonio Marra
Session: Proffered Paper session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA17 - Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)
Presenter: Laurence Buisseret
Session: Proffered Paper session: Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Invited Discussant 210O and LBA17
Presenter: Peter Schmid
Session: Proffered Paper session: Breast cancer, metastatic
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Breast cancer, metastatic
Resources:
Webcast